These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2223576)

  • 1. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
    Schuurhuis GJ; Broxterman HJ; Pinedo HM; van Heijningen TH; van Kalken CK; Vermorken JB; Spoelstra EC; Lankelma J
    Br J Cancer; 1990 Oct; 62(4):591-4. PubMed ID: 2223576
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
    Fujimoto S
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
    Fjällskog ML; Frii L; Bergh J
    Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Cremophor EL, solvent for paclitaxel, cytotoxic?
    Fjällskog ML; Frii L; Bergh J
    Lancet; 1993 Oct; 342(8875):873. PubMed ID: 8104306
    [No Abstract]   [Full Text] [Related]  

  • 6. Cremophor EL, solvent for paclitaxel, and toxicity.
    Liebmann J; Cook JA; Mitchell JB
    Lancet; 1993 Dec; 342(8884):1428. PubMed ID: 7901713
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
    Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
    Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
    Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A.
    Chervinsky DS; Brecher ML; Baker RM; Hoelcle MJ; Tebbi CK
    Cancer Biother; 1993; 8(1):67-75. PubMed ID: 7812351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 11. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
    Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
    J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line.
    Twentyman PR; Fox NE; White DJ
    Br J Cancer; 1987 Jul; 56(1):55-7. PubMed ID: 3040060
    [No Abstract]   [Full Text] [Related]  

  • 13. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of cremophor EL in the anaesthetized dog.
    Gaudy JH; Sicard JF; Lhoste F; Boitier JF
    Can J Anaesth; 1987 Mar; 34(2):122-9. PubMed ID: 3829297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C.
    Zhao FK; Chuang LF; Israel M; Chuang RY
    Biochem Biophys Res Commun; 1989 Mar; 159(3):1359-67. PubMed ID: 2930566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.
    Lorenz W; Schmal A; Schult H; Lang S; Ohmann C; Weber D; Kapp B; Lüben L; Doenicke A
    Agents Actions; 1982 Apr; 12(1-2):64-80. PubMed ID: 6177219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins.
    Twentyman PR
    Br J Cancer; 1988 Mar; 57(3):254-8. PubMed ID: 2833299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
    Webster LK; Cosson EJ; Stokes KH; Millward MJ
    Br J Cancer; 1996 Feb; 73(4):522-4. PubMed ID: 8595168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance by surfactants.
    Woodcock DM; Linsenmeyer ME; Chojnowski G; Kriegler AB; Nink V; Webster LK; Sawyer WH
    Br J Cancer; 1992 Jul; 66(1):62-8. PubMed ID: 1637678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
    Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
    Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.